See here for links to the Vaccine Trial reports and related information.
Pfizer BioNTech
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (NEJM)
Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020 (FDA Briefing Document)
Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) Lancet preprint Feb 2021
Oxford
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK : an interim analysis of four randomised controlled trials in Brazil, South Africa, and of the controlled trials in Brazil, South Africa, and the UK (Lancet)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Nature
Medicine
Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca WHO Feb 2021
JCVI Statement on the use of the AstraZeneca Covid-19 Vaccine 7th April 2021 (Govt. Website)
COVID-19 vaccination: blood clotting information for healthcare professionalwww.gov.uk/government/publications/covid-19-vaccination-blood-clotting-information-for-healthcare-professionals#2021-04-07T16:50:44Zs Govt information
Moderna
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine NEJM
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults NEJM
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report NEJM
Johnson and Johnson
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine NEJM
Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021 FDA Briefing Document
Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19
Sputnik
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Lancet
Concerns re available trial data
Vasiliy Vlassov: Sputnik V and Russia’s covid-19 vaccine race with link to further article expressing concerns
Pfizer BioNTech
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (NEJM)
Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020 (FDA Briefing Document)
Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) Lancet preprint Feb 2021
Oxford
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK : an interim analysis of four randomised controlled trials in Brazil, South Africa, and of the controlled trials in Brazil, South Africa, and the UK (Lancet)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses Nature
Medicine
Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca WHO Feb 2021
JCVI Statement on the use of the AstraZeneca Covid-19 Vaccine 7th April 2021 (Govt. Website)
COVID-19 vaccination: blood clotting information for healthcare professionalwww.gov.uk/government/publications/covid-19-vaccination-blood-clotting-information-for-healthcare-professionals#2021-04-07T16:50:44Zs Govt information
Moderna
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine NEJM
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults NEJM
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report NEJM
Johnson and Johnson
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine NEJM
Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021 FDA Briefing Document
Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19
Sputnik
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Lancet
Concerns re available trial data
Vasiliy Vlassov: Sputnik V and Russia’s covid-19 vaccine race with link to further article expressing concerns
